About Portage Biotech
Portage Biotech is a publicly listed company based in Tortola (British Virgin Islands) founded in 2013. Therapeutics based on Cell Permeable Peptide Platform. Portage Biotech has completed 2 acquisitions, including Tarsus Rx and Tarus Therapeutics. Its chief executive, as recorded, is Alexander Pickett. Portage Biotech offers products and services including iNKT Platform, Adenosine Platform, and Other Programs. Its focus areas include Life Sciences, Oncology, Drugs and Diversified. Its legal entity is PORTAGE INC.
Company details
Portage Biotech was founded in 2013 in Tortola and operates in the biotechnology sector, focusing on pharmaceutical product development through clinical proof of concept. Emphasis is placed on orphan drugs and targeted therapies for cancer, infectious diseases, neurology, and psychiatry. Products are licensed or sold to larger firms post-proof. Subsidiaries include Portage Pharmaceuticals Ltd for CPP-based treatments and Biohaven for glutamatergic agents addressing neuropsychiatric disorders.
- Headquarters Tortola, British Virgin Islands
- Stage Public
- SectorsHealthcare
- Email••••••••
- Website portagebiotech.com
- Social LinkedIn X
- Legal Name Portage Biotech Inc.
- Annual Revenue$97 K (USD)as on Mar 31, 2026
- Net Profit-$38.63 M (USD)-470.8as on Mar 31, 2026
- EBITDA-$22.9 M (USD)-210.21as on Mar 31, 2026
- Latest Funding Round$36.08M (USD), Post-IPO
Sep 2025
- Investments & AcquisitionsTarsus Rx
& 1 more
Products & Services of Portage Biotech
Portage Biotech offers a comprehensive portfolio of products and services, including iNKT Platform, Adenosine Platform, and Other Programs.
Develops therapies targeting cancer resistance pathways through immune activation
Focuses on novel assets for cancer treatment via adenosine modulation
Advances preclinical assets for diverse cancer resistance mechanisms
Funding Insights of Portage Biotech
- Total Rounds 6
- Last Round Post-IPO — $36.08M
- First Round $3.4M
(Jun 2015)
All 6 funding rounds of Portage Biotech with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep 2025 | $36.08M | Post-IPO | – | – | – |
| Jan 2025 | $1.49M | Post-IPO | – | – | – |
| Aug 2022 | $34.64M | Post-IPO | – | – | – |
| May 2020 | $6.79M | Post-IPO | – | – | – |
| Jun 2015 | $1.6M | Post-IPO | – | – | – |
| Jun 2015 | $3.4M | Post-IPO | – | – | – |
People of Portage Biotech
2 people are tracked at Portage Biotech (2 in leadership).
| Name | Role | Group |
|---|---|---|
Alexander Pickett | CEO | Leadership |
Andrea Park | Chief Financial Officer | Leadership |
Complete people profiles for Portage Biotech
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Portage Biotech
Portage Biotech is a publicly listed company on the NASDAQ with ticker symbol ATON in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date30 Mar 2018
- Listed onNASDAQ: PRTG
- Listed entityPortage Biotech Inc.
- Exchange sectorHealth technology
- ISINVGG7185A1443
- Share price$0.32 · 2026-04-21
- Market capitalisation$7.5M
- Volume (last session)9,849,274
- Analyst consensusStrong buy
Financials of Portage Biotech
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | $97,000 | -$38.6M | -$22.9M |
| 2024 | -$6.8M | -$7.4M | |
| 2023 | -$75.3M | -$18.2M | |
| 2022 | -$104.6M | -$16.6M | |
| 2021 | -$16.9M | -$15.6M |
Detailed financial statements for Portage Biotech
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Portage Biotech
Portage Biotech has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include Tarsus Rx and Tarus Therapeutics.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Proprietary drugs for blepharitis treatment are developed by Tarsus. | tarsusrx.com | Irvine, United States | 2017 | Jul 2022 | •••• | |
Cancer therapeutics targeting the adenosine pathway are developed. | tarustx.com | New York, United States | 2019 | Jul 2022 | •••• |
Complete acquisition details for Portage Biotech
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Portage Biotech
6 dated milestones of Portage Biotech across 12 years, from founding to its latest funding, stage changes and deals.
- Founded Portage Biotech is founded.
- Funding First funding round of $3.4M.
- IPO Lists on the stock exchange (IPO).
- Acquisition Acquires Tarus Therapeutics.
- Acquisition Acquires Tarsus Rx.
- Funding Latest funding round, Post-IPO, of $36.1M.
Web traffic of Portage Biotech
The website of Portage Biotech (portagebiotech.com) receives about 3.2K visits a month.
- Monthly visits3.2K
▲ 15% vs previous month
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Portage Biotech
Complete news archive for Portage Biotech
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Portage Biotech
Portage Biotech was founded in 2013 and raised its 1st funding round 2 years after it was founded.
Portage Biotech is headquartered in Tortola, British Virgin Islands.
Alexander Pickett is the CEO of Portage Biotech, as recorded in our data.
Annual revenue of Portage Biotech is $97K as on Mar 31, 2026.
Portage Biotech was founded in 2013 in Tortola and operates in the biotechnology sector, focusing on pharmaceutical product development through clinical proof of concept. Emphasis is placed on orphan drugs and targeted therapies for cancer, infectious diseases, neurology, and psychiatry. Products are licensed or sold to larger firms post-proof. Subsidiaries include Portage Pharmaceuticals Ltd for CPP-based treatments and Biohaven for glutamatergic agents addressing neuropsychiatric disorders.
Portage Biotech offers iNKT Platform, Adenosine Platform, and Other Programs.
Yes, Portage Biotech is publicly traded on NASDAQ under the ticker symbol ATON.
Portage Biotech has made 2 acquisitions, including Tarsus Rx, and Tarus Therapeutics.
Portage Biotech operates through Portage Inc..